株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Gamida Cell Ltd.の製品パイプライン分析

Gamida Cell Ltd. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 251667
出版日 ページ情報 英文 21 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
Gamida Cell Ltd.の製品パイプライン分析 Gamida Cell Ltd. - Product Pipeline Review - 2015
出版日: 2015年10月30日 ページ情報: 英文 21 Pages
概要

Gamida Cell Ltd.はイスラエルに本社を置くヘルスケア企業で、白血病、リンパ腫、クラッベ病、異染性白質ジストロフィー、フルラー症候群、血液がん、末梢血管系疾患、神経系疾患の治療薬を提供しています。

当レポートでは、Gamida Cell Ltd.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Gamida Cell Ltd.の基本情報

  • Gamida Cell Ltd.の概要
  • 主要情報
  • 企業情報

Gamida Cell Ltd.:R&Dの概要

  • 主な治療範囲

Gamida Cell Ltd.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Gamida Cell Ltd.:パイプライン製品の概況

  • 後期段階にあるパイプライン製品
    • 第3相の製品/併用療法モダリティ
  • 臨床段階にあるパイプライン製品
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ

Gamida Cell Ltd.:薬剤プロファイル

  • StemEx
  • GC-003
  • NiCord
  • Stem Cells to Activate Natural Killer Cell for Adoptive Cell-Mediated Therapy
  • Mesenchymal Stem Cells for Immunology

Gamida Cell Ltd.:パイプライン分析

  • 投与経路別
  • 分子タイプ別

Gamida Cell Ltd.:最新のパイプライン情報

Gamida Cell Ltd.:本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07720CDB

Summary

Global Markets Direct's, 'Gamida Cell Ltd. - Product Pipeline Review - 2015', provides an overview of the Gamida Cell Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Gamida Cell Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Gamida Cell Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Gamida Cell Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Gamida Cell Ltd.'s pipeline products

Reasons to buy

  • Evaluate Gamida Cell Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Gamida Cell Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Gamida Cell Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Gamida Cell Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Gamida Cell Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Gamida Cell Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Gamida Cell Ltd. Snapshot
    • Gamida Cell Ltd. Overview
    • Key Information
    • Key Facts
  • Gamida Cell Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Gamida Cell Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Gamida Cell Ltd. - Pipeline Products Glance
    • Gamida Cell Ltd. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Gamida Cell Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Gamida Cell Ltd. - Drug Profiles
    • CordIn
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NiCord
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy to Activate Natural Killer Cell for Adoptive Cell-Mediated Therapy
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Gamida Cell Ltd. - Pipeline Analysis
    • Gamida Cell Ltd. - Pipeline Products by Route of Administration
    • Gamida Cell Ltd. - Pipeline Products by Molecule Type
  • Gamida Cell Ltd. - Recent Pipeline Updates
  • Gamida Cell Ltd. - Dormant Projects
  • Gamida Cell Ltd. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Gamida Cell Ltd., Key Information
  • Gamida Cell Ltd., Key Facts
  • Gamida Cell Ltd. - Pipeline by Indication, 2015
  • Gamida Cell Ltd. - Pipeline by Stage of Development, 2015
  • Gamida Cell Ltd. - Monotherapy Products in Pipeline, 2015
  • Gamida Cell Ltd. - Phase I, 2015
  • Gamida Cell Ltd. - Preclinical, 2015
  • Gamida Cell Ltd. - Pipeline by Route of Administration, 2015
  • Gamida Cell Ltd. - Pipeline by Molecule Type, 2015
  • Gamida Cell Ltd. - Recent Pipeline Updates, 2015
  • Gamida Cell Ltd. - Dormant Developmental Projects,2015

List of Figures

  • Gamida Cell Ltd. - Pipeline by Top 10 Indication, 2015
  • Gamida Cell Ltd. - Pipeline by Stage of Development, 2015
  • Gamida Cell Ltd. - Monotherapy Products in Pipeline, 2015
  • Gamida Cell Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • Gamida Cell Ltd. - Pipeline by Top 10 Molecule Type, 2015
Back to Top